Skip to content

Oncolinx

The next generation of cancer therapies.

From
Boston, MA

Founded
2013

Cohort Year: Y3 (2017)
Status: Inactive
HQ: Boston, MA

Y3 (2017) Life Sciences

Oncolinx, in conjunction with the National Cancer Institute, is developing antibody-drug conjugates (ADCs) that carry a patented, immune-activating drug payload called Azonafide exclusively to cancer cells. The Oncolinx platform is partnered with more than 14 leading pharmaceutical companies and 6 academic labs all over the world – concurrently developing ADCs across 30 different cancer indications.

Oncolinx Pitch at 43North Finals 2016

Founders

Sourav Sinha

CEO, Co-founder

Riley Ennis

COO